CDTX - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Cidara Therapeutics

Cidara Therapeutics (CDTX) management is undergoing a rigorous restructuring, seeking survival through new licensing agreements. The trailing twelve-month sales growth rate captures the results of this strategy, where the parameter value equals -100.00. Development relies on Cloudbreak automation to accelerate testing and a high level of authority in creating immunotherapies against dangerous infections.
cidara.com (CDTX) - פילוחי מדדים ודוחות פיננסיים

This indicator measures rolling year revenue dynamics relative to the same period last year, allowing for an assessment of management's ability to contain operating expenses amid revenue growth. By analyzing the relative change in rolling year revenue versus the prior year period, an investor can identify risks of payroll inflation, which is critical for Cidara Therapeutics (CDTX) when receiving interim partnership payments from pharma behemoths.